Navigation Links
Liquichek Specialty Immunoassay Control

ProductsLiquichek Specialty Immunoassay Control
Company Bio-Rad Laboratories
Item Liquichek Specialty Immunoassay Control
Features 
  • First liquid control with "multi-specialty analytes and excellent open-vial stability
  • Ideal for monitoring all Intact PTH assays, including Bioactive and Intra-operative Intact PTH test methods
  • Liquid, human serum based
  • 30 day open-vial stability at 28C for Intact PTH and most analytes
  • Multi-analyte control including both Anti-Tg and Anti-TPO
  • Includes three clinically significant levels for these specialty analytes
  • Assayed values available for most automated immunoassay analyzers
  • UNITY Quality Control Program available for interlaboratory comparisons
Description Liquichek Specialty Immunoassay Control is a unique liquid assayed control designed to complement the popular Lyphochek and Liquichek Immunoassay Plus Controls. This product is specially formulated to include more complex analytes and provide excellent open-vial stability.
Info Bio-Rad Laboratories
Customer Service: 1-800-2-BIORAD
Web site: http://www.bio-rad.com

Related medicine products :

1. Liquichek Rheumatoid Factor Control
2. Liquichek Immunology Control
3. Liquichek Immunoassay Plus Control
4. Liquichek Spinal Fluid Control
5. Liquichek Urine Chemistry Control
6. Liquichek Whole Blood Volatiles Control
7. Liquichek Urinalysis Control
8. Liquichek Serum Volatiles Control
9. Liquichek Therapeutic Drug Monitoring Control (TDM)
10. Liquichek Autoimmune Controls - ANA
11. Liquichek Pediatric Control
Kinetic and endpoint methods for the quantitative determination of creatinine in serum....
For the qualitative determination of magnesium in serum....
For the quantitative determination of total glucose in human serum....
Intended for the quantitative determination of glucose in biological fluids. Reaction: endpoint. Wavelength: 340 nm. Linearity: 800 mg/dL (44.4 mmol/L). Single vial, dry powder reagent....
Medicine Products:
(Date:6/25/2017)... ... 2017 , ... CareSet Labs released the Root NPI Graph today at the ... greatly improved version of the Doctor Referral teaming dataset commonly available from Medicare. , ... called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... at 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable ... that visits to the dentist fit into their patients’ busy lifestyles. Dental365 also ...
(Date:6/23/2017)... CA (PRWEB) , ... June 23, 2017 , ... By ... earned its ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ... the top 1% of all charities reviewed by Charity Navigator and earns ANRF a ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend ... entry to the JFK Virgin Atlantic lounge. , Bensko is no stranger to ... years ago, Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... Cancer Conference from Sept. 18 to 20. , The two-day conference is focused ... with the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/13/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... Food and Drug Administration (FDA) has notified the Company that ... Zhejiang, China manufacturing facility has been ... clearance of the Warning Letter related to our ... of the progress we have made in our ongoing quality ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company (NYSE: ... three Phase 3 studies of galcanezumab, an investigational treatment ... late-breaking data on several key secondary endpoints for galcanezumab ... from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be ... scientific meeting in Boston . ...
Breaking Medicine Technology: